Surgical company TELA Bio Inc and Aroa Biosurgery Thursday jointly announced the receipt of the the US Food and Drug Administration's (FDA) 510(k) clearance to market OviTex RBS for hernia repair and abdominal wall reconstructions, including the most complex cases.
Following the US FDA"s marketing approval, TELA Bio will now launch the OviTex Permanent product line commercially in US from in large sizes up to 25x40 cm (1,000 cm2), which is a 150% surface area increase over currently available devices.
A distinct class of surgical mesh, OviTex RBSs are the only devices available that reinforce biologic materials with polymer fibres in a unique embroidered construction that allows for functional tissue remodelling, as well as improved strength and handling.
TELA's OviTex Reinforced BioScaffolds (RBSs) products are intended for use as a surgical mesh to reinforce and/or repair soft tissue where weakness exists. Indications for use include the repair of hernias and/or abdominal wall defects that require the use of reinforcing or bridging material to obtain the desired surgical outcome.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT